4-(Hydroxymethyl)-5-methyl-1,3-dioxol-2-one, 90.0%, 25g

Diethylene glycol, min. 99%, for synthesis, 2.5 l, plastic packaging.

3-iodotetrahydrothiophene 1,1-dioxide, 95.0%, 250mg

3-(2-Amino-6-(1-((6-(2-hydroxypropan-2-yl)pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile, 98.0%, 100mg

2-(4-Aminophenyl)-1H-benzo[d]imidazol-5-amine, 95.0%, 25g

(2R,3S,5R)-5-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol, 95.0%, 250mg

4-(6-Bromopyrazin-2-yl)morpholine, 95.0%, 1g

(S)-N,N-Dimethyl-1-[(R)-1',2-bis(diphenylphosphino)ferrocenyl]ethylamine>95.0%(HPLC)100mg

3-Bromo-2-iodophenol, 95.0%, 1g

3-Fluoro-4-nitrobenzaldehyde>97.0%(GC)5g

CLINAFLOXACIN, 95%, 100mg

2-(2-Phenoxy-acetylamino)-3-phenyl-propionic acid, 95.0%, 250mg

Sodium hydroxide solution 45%, extra pure, 25 l, plastic packaging.